Anti-CD19 antibody-drug conjugate therapy in B cell non-Hodgkin lymphoma

被引：0
|
作者：
Saito, Chieko
Bi, Chengfeng
Fu, Kai
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-2655
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2655
引用
收藏
页数：2
相关论文
共 50 条
  • [1] AN ANTI-CD79B ANTIBODY-DRUG CONJUGATE IS ACTIVE IN NON-HODGKIN LYMPHOMA
    不详
    CANCER DISCOVERY, 2015, 5 (06) : 576 - 576
  • [2] A novel antibody-drug conjugate anti-CD19(Fab)-LDM in the treatment of B-cell non-Hodgkin lymphoma xenografts with enhanced anticancer activity
    Jiang, Linlin
    Yang, Ming
    Zhang, Xiaoyun
    Bao, Shiqi
    Ma, Li
    Fan, Dongmei
    Zhou, Yuan
    Xiong, Dongsheng
    Zhen, Yongsu
    JOURNAL OF DRUG TARGETING, 2016, 24 (01) : 47 - 57
  • [3] Anti-CD19 CAR T-Cell Therapy for B-Cell Non-Hodgkin Lymphoma
    Abramson, Jeremy S.
    TRANSFUSION MEDICINE REVIEWS, 2020, 34 (01) : 29 - 33
  • [4] Development and Integration of Antibody-Drug Conjugate in Non-Hodgkin Lymphoma
    Mehta, Amitkumar
    Forero-Torres, Andres
    CURRENT ONCOLOGY REPORTS, 2015, 17 (09)
  • [5] Development of novel anti-CD19 antibody-drug conjugates for B-cell lymphoma treatment
    Li, Zhuanglin
    Wang, Mingxue
    Yao, Xuejing
    Li, Huanzhao
    Li, Shenjun
    Liu, Lina
    Yu, Deling
    Li, Xue
    Fang, Jianmin
    Huang, Changjiang
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2018, 62 : 299 - 308
  • [6] Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma
    Dornan, David
    Bennett, Fiona
    Chen, Yvonne
    Dennis, Mark
    Eaton, Dan
    Elkins, Kristi
    French, Dorothy
    Go, Mary Ann T.
    Jack, Andrew
    Junutula, Jagath R.
    Koeppen, Hartmut
    Lau, Jeffrey
    McBride, Jacqueline
    Rawstron, Andy
    Shi, Xiaoyan
    Yu, Nancy
    Yu, Shang-Fan
    Yue, Peng
    Zheng, Bing
    Ebens, Allen
    Polson, Andrew G.
    BLOOD, 2009, 114 (13) : 2721 - 2729
  • [7] Antibody-drug conjugates in non-Hodgkin lymphoma
    Lim, Soon Thye
    LANCET ONCOLOGY, 2015, 16 (06): : 607 - 608
  • [8] The Anti-CD19 Antibody-Drug Conjugate Loncastuximab Tesirine Achieved Responses in Patients with Diffuse Large B-Cell Lymphoma Who Relapsed after Anti-CD19 CAR T-Cell Therapy
    Caimi, Paolo F.
    Ardeshna, Kirit M.
    Reid, Erin
    Ai, Weiyun Z.
    Lunning, Matthew A.
    Zain, Jasmine
    Solh, Melhem
    Kahl, Brad S.
    Hamadani, Mehdi
    BLOOD, 2021, 138
  • [9] Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma
    Caimi, Paolo F.
    Pacheco Sanchez, Gabriela
    Sharma, Ashish
    Otegbeye, Folashade
    Ahmed, Nausheen
    Rojas, Patricio
    Patel, Seema
    Kleinsorge Block, Sarah
    Schiavone, Jennifer
    Zamborsky, Kayla
    Boughan, Kirsten
    Hillian, Antoinette
    Reese-Koc, Jane
    Maschan, Mikhail
    Dropulic, Boro
    Sekaly, Rafick-Pierre
    De Lima, Marcos
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [10] A phase I study of TRS005: An anti-CD20-MMAE antibody-drug conjugate, in relapsed or refractory b cell non-Hodgkin lymphoma
    Shi, Y-K.
    Li, Z-M.
    Qing, Y.
    Zhang, H.
    Jia, Y.
    Jing, H.
    Li, Y.
    Tong, X.
    Liu, H.
    Li, L.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S827 - S827
12345